Австралия - английски - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Израел - английски - Ministry of Health

j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Израел - английски - Ministry of Health

j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Малта - английски - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Европейски съюз - английски - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - bortezomib - multiple myeloma - antineoplastic agents - bortezomib sun as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib sun in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib sun in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib sun in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Малта - английски - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Малта - английски - Medicines Authority

koanaa healthcare limited 4th floor, cavendish house, 369 burnt oak, broadway, edgware, ha85aw, middlesex, united kingdom - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Австралия - английски - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - - velcade, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. - velcade, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - velcade is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. - velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Израел - английски - Ministry of Health

neopharm (israel) 1996 ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - multiple myelomabortezomib fresenius kabi is indicated for the treatment of adult patients with multiple myeloma.mantle cell lymphomabortezomib fresenius kabi for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib fresenius kabi in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Европейски съюз - английски - EMA (European Medicines Agency)

accord healthcare s.l.u. - bortezomib - multiple myeloma - antineoplastic agents - bortezomib accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.